Galapagos (ADR) (GLPG)
Belgian biotech shifting from cell therapy toward partnered immunology and oncology assets.
Something off on this page? Send us feedback.
Galapagos is a Mechelen, Belgium-based biotechnology company focused on serious diseases, now rebuilding its pipeline through business development. Its near-term work centers on immunology programs such as GLPG3667 and a Gilead-linked T-cell engager collaboration, while its former cell therapy portfolio is being wound down.
Galapagos is a Belgian biotechnology company headquartered in Mechelen and listed on Nasdaq. The company has moved from an internally built drug-discovery and cell-therapy model toward a leaner business-development strategy, using partnerships, licenses, and acquisitions to rebuild a clinical pipeline. Its current focus areas are immunology and inflammation, oncology, and adjacent serious diseases where it can acquire or partner clinically tested assets.
GLPG3667, a TYK2 inhibitor, remains the main internal immunology program, while a framework agreement with Gilead gives Galapagos rights and operating assets around gamgertamig, a BCMAxCD3 T-cell engager for autoimmune disease. The legacy oncology cell-therapy programs are being wound down, and future scale depends on completing collaborations, securing regulatory progress, and selecting external assets that can survive clinical testing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $3.46B · Total debt $7.5M · Total assets $3.91B · Shareholders' equity $3.77B
- Revenue
- $14.3M
- Operating income
- −$53.1M
- Net income
- $2.5M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions79 holders · as of Jun 30, 2026 | 48.65% | 32.06M ADS | |
| Otherremainder | 51.35% | 33.84M ADS |
65.90M ADS as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Gilead Sciences, Inc.Institution | 25.35% | 16.71M ADS | 13Fas of Jun 30, 2026 |
Tang Capital Management LLCInstitution | 5.75% | 3.79M ADS | 13Fas of Jun 30, 2026 |
Madison Avenue International LPInstitution | 5.47% | 3.61M | 13Gfiled Jun 23, 2026 ↗ |
Madison Avenue Partners, LPInstitution | 5.23% | 3.45M ADS | 13Fas of Jun 30, 2026 |
Sands Capital Management, LLCInstitution | 4.39% | 2.89M | 13Gfiled Jan 10, 2019 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.